SalC presents potential as a therapeutic agent, providing robust anti-inflammatory and antioxidant effects against AKI, mediated by the inhibition of signaling axes involving TLR-4, NF-κB, MAPK, HO-1, and Nrf2. Here, TLR4 is linked to acute kidney injury.